Vincerx Pharma, Inc. (VINC) News
Filter VINC News Items
VINC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VINC News Highlights
- VINC's 30 day story count now stands at 2.
- Over the past 9 days, the trend for VINC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about VINC are ADC, ALTO and DEC.
Latest VINC News From Around the Web
Below are the latest news stories about VINCERX PHARMA INC that investors may wish to consider to help them evaluate VINC as an investment opportunity.
15 Best Falling Stocks To Buy NowIn this article, we will take a detailed look at the 15 Best Falling Stocks To Buy Now. For a quick overview of such stocks, read our article 5 Best Falling Stocks To Buy Now. The Wall Street is headed to end 2023 on a strongly positive note as the Fed’s indication of coming rate cuts have infused a […] |
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class CXCR5-targeted ADC from our VersAptx platform, shows superior activity and safety compared with commercially available B-cell targeted ADCs PALO ALTO, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical need |
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatePhase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort Phase 1 dose escalation for VIP236 - first-in-class small molecule-drug conjugate (SMDC) for treatment of solid tumors - progressing well with optimized dosing schedule Phase 1 dose escalation combination study for enitociclib in collaboration with NIH - partial response in first patient dosed in second cohort Ca |
Vincerx Pharma To Present Three Posters at ASH 2023 in DecemberVIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster expands potential clinical indications PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today annou |
New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business NetworkAirings start on Bloomberg TV on Saturday, October 14, 2023, at 6:30 PM ET, followed by the FOX Business Network show on Sunday, October 15, 2023, at 3:30 PM ET New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network Episodes 521/522: 1).Vincerx Pharma, Inc. (NASDAQ: VINC) ($VINC) 2). Surf Air Mobility, Inc. (NYSE: SRFM) ($SRFM) 3). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 4). Mangoceuti |
New to The Street Announces TV Corporate Appearances, Broadcasting Episode 518 on Newsmax and Episode 519 on FOX Business Network, Airings start on Saturday, October 7, 2023, at 3:30 PM ETNew to The Street Announces TV Corporate Appearances, broadcasting Episode 518 on Newsmax and Episode 519 on FOX Business Network, Airings start on Saturday, October 7, 2023, at 3:30 PM ET Show 518/591 feature: 1). Vincerx Pharma, Inc. (Nasdaq: VINC) ($VINC) 2). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 3). Kohler Tax Associates 4) Hope Tian Oil Painting5) Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®) - https://www.newtothestreet.com/ New t |
Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s CEO Ahmed Hamdy, M.D. and the Management Team will participate in a panel presentation and one-on-one investor meetings at the Cantor Fitzgerald Global Healthcare Conference 2023, to be held in New York, NY, September 26-28, 2023. Conference |
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALLPALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that the first patient has been dosed in the Phase 1 trial evaluating VIP943 in patients with relapsed/refractory acute myeloid leukemia (R/R AML), myelodysplastic sy |
Vincerx Pharma Announces FDA Clearance of IND for VIP943Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development and regulatory expertise PALO ALTO, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that it has received clearance for |
10 Oversold Penny Stocks To BuyIn this article, we will take a look at the 10 oversold penny stocks to buy. To see more such companies, go directly to 5 Oversold Penny Stocks To Buy. As markets rebound on the back of declining inflation and hopes that the Federal Reserve might be close to winning its battle against inflation, investors […] |